J Hornberger

Summary

Affiliation: The SPHERE Institute/Acumen
Country: USA

Publications

  1. ncbi request reprint A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy
    John Hornberger
    The SPHERE Institute Acumen, LLC, Burlingame, California, USA
    Med Decis Making 27:789-821. 2007
  2. ncbi request reprint Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
    John Hornberger
    SPHERE Institute and Acumen LLC, Burlingame, California 94010, USA
    Ann Intern Med 145:317-25. 2006
  3. ncbi request reprint Recognition, diagnosis, and treatment of primary focal hyperhidrosis
    John Hornberger
    Stanford University School of Medicine, USA
    J Am Acad Dermatol 51:274-86. 2004
  4. ncbi request reprint The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase
    J Hornberger
    Acumen LLC The SPHERE Institute, Burlingame, CA 94010, USA
    J Viral Hepat 13:377-86. 2006
  5. ncbi request reprint Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer
    John Hornberger
    The SPHERE Institute Acumen, LLC, Burlingame, CA 94010, USA
    Am J Manag Care 11:313-24. 2005
  6. ncbi request reprint Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy
    John Hornberger
    The SPHERE Institute Acumen, LLC, 1415 Rollins Road, Suite 110, Burlingame, CA 94010, USA
    HIV Clin Trials 6:92-102. 2005
  7. ncbi request reprint Comprehensive evaluations of health care interventions: the realism-transparency tradeoff
    John Hornberger
    ACUMeN, LLC, Burlingame, CA 94010, USA
    Med Decis Making 25:490-2. 2005
  8. ncbi request reprint Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States
    John Hornberger
    The SPHERE Institute Acumen, Burlingame, California 94010, USA
    AIDS Res Hum Retroviruses 22:240-7. 2006
  9. ncbi request reprint Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection
    John Hornberger
    The SPHERE Institute Acumen, LLC, Burlingame, CA 94010, USA
    J Clin Virol 36:283-91. 2006
  10. ncbi request reprint Deciding eligibility for transplantation when a donor kidney becomes available
    J Hornberger
    Department of Health Research and Policy, Stanford University School of Medicine, CA 94305 5092, USA
    Med Decis Making 17:160-70. 1997

Detail Information

Publications18

  1. ncbi request reprint A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy
    John Hornberger
    The SPHERE Institute Acumen, LLC, Burlingame, California, USA
    Med Decis Making 27:789-821. 2007
    ..To determine whether gaps exist in published cost-utility analyses as measured by their coverage of topics addressed in current HIV guidelines from the Department of Health and Human Services (DHHS)...
  2. ncbi request reprint Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
    John Hornberger
    SPHERE Institute and Acumen LLC, Burlingame, California 94010, USA
    Ann Intern Med 145:317-25. 2006
    ..12 to 5.42 cases per 1000 person-years. Median follow-up was 3.1 years, and relative risk reduction was 51.3% (95% CI, 44.2% to 57.6%)...
  3. ncbi request reprint Recognition, diagnosis, and treatment of primary focal hyperhidrosis
    John Hornberger
    Stanford University School of Medicine, USA
    J Am Acad Dermatol 51:274-86. 2004
  4. ncbi request reprint The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase
    J Hornberger
    Acumen LLC The SPHERE Institute, Burlingame, CA 94010, USA
    J Viral Hepat 13:377-86. 2006
    ..Thus treatment of PNALT with peginterferon alpha-2a (40 kDa) plus ribavirin is projected to reduce the incidence of cirrhosis, increase life expectancy and have an acceptable cost-effectiveness ratio from a societal perspective...
  5. ncbi request reprint Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer
    John Hornberger
    The SPHERE Institute Acumen, LLC, Burlingame, CA 94010, USA
    Am J Manag Care 11:313-24. 2005
    ....
  6. ncbi request reprint Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy
    John Hornberger
    The SPHERE Institute Acumen, LLC, 1415 Rollins Road, Suite 110, Burlingame, CA 94010, USA
    HIV Clin Trials 6:92-102. 2005
    ..Enfuvirtide (ENF) plus an optimized background (OB) antiretroviral regimen delays virological failure (VF), reduces HIV-1 viral load, and increases CD4 count compared with OB only in pretreated patients...
  7. ncbi request reprint Comprehensive evaluations of health care interventions: the realism-transparency tradeoff
    John Hornberger
    ACUMeN, LLC, Burlingame, CA 94010, USA
    Med Decis Making 25:490-2. 2005
  8. ncbi request reprint Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States
    John Hornberger
    The SPHERE Institute Acumen, Burlingame, California 94010, USA
    AIDS Res Hum Retroviruses 22:240-7. 2006
    ..5 years among treatment-experienced HIV-infected patients. The cost-effectiveness of ENF is comparable to many existing treatment and prevention management strategies for HIV...
  9. ncbi request reprint Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection
    John Hornberger
    The SPHERE Institute Acumen, LLC, Burlingame, CA 94010, USA
    J Clin Virol 36:283-91. 2006
    ..The cost-effectiveness of treating these patients with peginterferon alfa-2a/ribavirin has yet to be explored from a US societal perspective...
  10. ncbi request reprint Deciding eligibility for transplantation when a donor kidney becomes available
    J Hornberger
    Department of Health Research and Policy, Stanford University School of Medicine, CA 94305 5092, USA
    Med Decis Making 17:160-70. 1997
    ..Graft survival rates and quality-adjusted life expectancies may increase by as much 6.7% and 1.6 months, respectively, with only a slight increase (< 0.4 months) in the quality-adjusted waiting time until transplantation...
  11. ncbi request reprint Capecitabine plus docetaxel combination therapy
    Shailendra Verma
    Department of Medical Oncology, Ottawa Regional Cancer Centre, Ottawa, Canada
    Cancer 103:2455-65. 2005
    ..The current study evaluated the cost-effectiveness of the capecitabine/docetaxel combination versus docetaxel monotherapy, comparing the gain in quality-adjusted survival with associated health care costs...
  12. ncbi request reprint Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies
    Milton C Weinstein
    Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Value Health 6:9-17. 2003
    ..This report describes the consensus of a task force convened to provide modelers with guidelines for conducting and reporting modeling studies...
  13. ncbi request reprint Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies
    Gary H Lyman
    Department of Medicine, James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    Cancer 109:1011-8. 2007
    ..The predictive accuracy for treatment efficacy also underwent validation in 651 patients randomized on NSABP B-20 and 645 patients on NSABP B-14...
  14. ncbi request reprint Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma
    Jennie H Best
    Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Value Health 8:462-70. 2005
    ....
  15. ncbi request reprint Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-naive HIV-1-infected US veterans (1992-2004)
    Mark Holodniy
    AIDS Research Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94340, USA
    J Acquir Immune Defic Syndr 44:20-9. 2007
    ..To analyze temporal patterns of antiretroviral (ARV) prescribing practices relative to nationally defined guidelines in treatment-naive patients with HIV-1 infection...
  16. ncbi request reprint Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients
    Anatole Besarab
    Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI, USA
    Am J Kidney Dis 40:439-46. 2002
    ....
  17. pmc Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
    John Hornberger
    Cedar Associates LLC, Menlo Park, CA, USA
    Leuk Lymphoma 49:227-36. 2008
    ..The cost-effectiveness ratio of R-CVP compared with CVP is projected to be cost-effective in the United States under a range of sensitivity analyses...
  18. doi request reprint Rechargeable spinal cord stimulation versus non-rechargeable system for patients with failed back surgery syndrome: a cost-consequences analysis
    John Hornberger
    Cedar Associates LLC, Menlo Park, CA 94025, USA
    Clin J Pain 24:244-52. 2008
    ..The study objective is to estimate the average difference in lifetime costs between rechargeable and non-rechargeable pulse generators used in treatment with SCS for failed back surgery syndrome...